TD Cowen Forecasts Strong Price Appreciation for Agilent Technologies (NYSE:A) Stock

Key Points

• TD Cowen raised its price target for Agilent Technologies from $150 to $162, indicating a potential upside of 17.03% from the current stock price.
• Agilent Technologies received multiple upgrades, with a notable increase from UBS from a "neutral" to a "buy" rating and a price target boost to $170.
• The company's recent quarterly earnings met expectations with a reported EPS of $1.37, alongside a revenue of $1.74 billion, surpassing analyst estimates.

Agilent Technologies (NYSE:A - Get Free Report) had its price target raised by research analysts at TD Cowen from $150.00 to $162.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the medical research company's stock. TD Cowen's price target would indicate a potential upside of 17.03% from the stock's current price.

A has been the subject of a number of other reports. Rothschild Redb upgraded Agilent Technologies to a "strong-buy" rating in a research note on Wednesday, October 8th. UBS Group raised shares of Agilent Technologies from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $130.00 to $170.00 in a research report on Wednesday, October 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of Agilent Technologies in a research report on Wednesday, October 8th. Barclays raised their price objective on Agilent Technologies from $125.00 to $150.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 2nd. Finally, Rothschild & Co Redburn started coverage on shares of Agilent Technologies in a research note on Wednesday, October 8th. They set a "buy" rating and a $165.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies currently has a consensus rating of "Moderate Buy" and an average target price of $149.62.

Agilent Technologies Stock Up 1.3%

Agilent Technologies stock opened at $138.43 on Tuesday. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The firm has a market cap of $39.24 billion, a price-to-earnings ratio of 32.49, a PEG ratio of 4.46 and a beta of 1.26. The stock has a fifty day simple moving average of $125.51 and a two-hundred day simple moving average of $117.17. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts' consensus estimates of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business's revenue for the quarter was up 10.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities analysts predict that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Agilent Technologies by 1.8% during the second quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company's stock valued at $4,012,086,000 after acquiring an additional 589,219 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Agilent Technologies by 10.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company's stock worth $1,560,964,000 after buying an additional 1,273,994 shares in the last quarter. Geode Capital Management LLC grew its holdings in Agilent Technologies by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company's stock valued at $860,137,000 after buying an additional 115,183 shares in the last quarter. Generation Investment Management LLP grew its holdings in shares of Agilent Technologies by 15.9% in the second quarter. Generation Investment Management LLP now owns 5,775,860 shares of the medical research company's stock valued at $681,609,000 after purchasing an additional 792,304 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its position in Agilent Technologies by 2.5% in the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company's stock worth $624,888,000 after purchasing an additional 128,131 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.